Industry / Israel
If you would like to subscribe to Middle East & Africa Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Middle East & Africa Pharma & Healthcare Insight please click on the trial link below.
Teva Commits To In-House API Manufacturing
October 2007 | Company News AlertSorry, you must be a subscriber to view this article in full. If you are a subscriber please login.
If you would like to subscribe to Middle East & Africa Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Middle East & Africa Pharma & Healthcare Insight please click on the trial link below.
Israel's generics heavyweight Teva Pharmaceutical Industries has announced it is to invest a massive US$149mn in its local facilities over the next three years. The majority of the investment will be channelled to Teva-Tech, part of its active pharmaceutical (API) division, signalling it plans to take on up-and-coming API manufacturers based in emerging Asian markets. Teva-Tech operates a US FDA-approved high-volume API manufacturing plant in Israel, which also produces some niche products such as Vitamin D